Alle Storys
Folgen
Keine Story von Sartorius AG mehr verpassen.

Sartorius AG

euro adhoc: Sartorius AG
Quarterly or Semiannual Financial Statements
Sartorius' Third-Quarter Earnings Considerably Improved (E)

Disclosure announcement transmitted by euro adhoc. The issuer is
responsible for the content of this announcement.
- The success of its restructuring clearly visible
- An EBIT figure of 4.9 million euros was achieved in the third
quarter
- On a nine-month basis, EBIT at 1.4 million euros is also positive
again
- Sales revenue is up 6.9 percent
Thanks to the successful completion of restructuring in the
Industrial Mechatronics business area and to further process
improvements at the "Plant 2001," the Sartorius Group achieved a
turnaround in its third-quarter results. After reporting negative
earnings before interest and taxes for two quarters (-0.3 and -3.3
million euros, resp.), the Group was able to achieve a considerably
positive EBIT of 4.9 (1.6) million euros. Cumulatively, the Group's
EBIT figure at 1.4 (8.9) million euros is therefore also positive
again. Third-quarter EBIT adjusted for the expenses needed to build
up the organization at Vivascience were 6.5 (3.7) million euros. At
28.4 (28.5) million euros, adjusted earnings before interest, taxes,
depreciation and amortization, EBITDA, on a nine-month basis was
nearly at last year's level.
Already in the third quarter, the impact of the restructuring
successfully completed in the Industrial Mechatronics business area
could be substantially felt. Therefore, as early as the third
quarter, the Mechatronics Division could achieve a balanced result
again on a quarterly basis. In addition, our cost-saving measures
also had a positive effect on net cash flow, which at 5.1 million
euros attained a highly positive level again in the third quarter.
This enabled the Group to reduce its net debt by 4.2 million euros to
136.0 million euros on the reporting date of September 30, 2002,
compared with June 30, 2002.
As of September 30, 2002, the sales revenue of the Sartorius Group
rose by 6.9 percent to 347.3 million euros from 325.0 reported for
the year-earlier period, whereas order intake declined by 5.1 percent
because the figure posted for last year's period included a large
order received by our subsidiary BBI, among other things.
In view of its considerably improved third-quarter earnings and in
anticipation of being able to maintain this trend in the fourth
quarter, the Sartorius Group continues to aim at achieving an
increase in sales revenue and earnings for the full year of 2002
relative to the financial year of 2001. Beyond this, the company sees
excellent prospects for fiscal 2003. This forecast is based on two
assumptions: first, a major part of the loss in the first half of
2002, which could be attributed to non-recurring restucturing
expenses, are not likely to be generated in the following year.
Second, we assume that the average use of production capacity at our
"Plant 2001" will continue to increase during the coming year so that
this would further improve the cost ratios.
end of announcement        euro adhoc 11.11.2002

Further inquiry note:

Dr. Joachim Kreuzburg Tel.: +49 (0) 551 308 3438 E-Mail: info.investor@sartorius.com

Branche: Biotechnology
ISIN: DE0007165607
WKN: 716563
Index: SDAX, SMAX
Börsen: Baden-Württembergische Wertpapierbörse / free trade
Bayerische Börse / free trade
Berliner Wertpapierbörse / free trade
Börse Düsseldorf / free trade
Bremer Wertpapierbörse (BWB) / free trade
Hamburger Wertpapierbörse / free trade
Frankfurter Wertpapierbörse / official dealing
Niedersächsische Börse zu Hannover / official dealing